Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial enrolled 51 people across two groups — 12 participants in Cohort A and 39 in Cohort B. The trial was measuring how the body responded to treatment for hepatitis C (HCV), a virus that affects the liver. The main thing being tracked was whether the virus became undetectable in participants' blood 12 weeks after finishing treatment — a result researchers call "SVR12" (sustained virologic response at 12 weeks). A number of additional measures were also tracked at different points during and after treatment. The reported data shows that for the main outcome (virus undetectable at 12 weeks after treatment), 91.7% of Cohort A participants and 89.7% of Cohort B participants reached that point. For the additional measures: at week 4 of treatment, the virus was undetectable in 91.7% of Cohort A and 76.9% of Cohort B; at week 12 of treatment, those figures were 91.7% and 92.3% respectively; and by the end of the full treatment course, 100% of participants in both groups had undetectable virus levels. At 24 weeks after finishing treatment, the reported figures were lower — 66.7% for Cohort A and 30.8% for Cohort B. The reported data also shows that 0% of participants in either group experienced certain blood abnormalities (low red blood cells, low white blood cells, or low platelets) during treatment. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
View full results on ClinicalTrials.gov ↗
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Phase 3 Haemophilia Trial, Completed
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You have severe hemophilia, meaning your body produces less than 1% of the normal level of the clotting factor affected.
- You have been infected with the hepatitis C virus (HCV) and also have hemophilia.
- You are male and 18 years of age or older.
- You have never previously been treated with a medication called interferon.
Who may not be able to join:
- You are also infected with hepatitis B virus (HBV) or HIV.
- You have long-term liver disease caused by something other than hepatitis C.
- You have a substance in your blood called a Bethesda inhibitor, which can interfere with hemophilia treatment (confirm with trial site).
- You currently have, or have a history of, high blood pressure in the vein that carries blood to your liver (a condition called portal hypertension).
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Bristol-Myers Squibb, Bristol-Myers Squibb
Australian sites
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
5 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Percentage of Participants Who Achieved Sustained Virologic Response (SVR12) at Follow-Up Week 12
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.